BPC-157 / Providers, evidence & the fine printOur approach
Compare providers

Provider review

Promise BPC-157 review: the second charge deserves a look

The listing makes a first-payment offer. Compare the repeating bill, included care and exact product before acting on it.

We may earn a commission from qualifying provider referrals. Affiliate placements are labeled Partner. How we are funded

On this page

At a glance / Promise

Our take

Promise supplies a clear introductory-versus-renewal distinction and a package description. The practical questions concern the precise product, individual access, follow-up and refund timing. Those are good consultation checklist items. Human evidence should be assessed on its own terms; a visible service price does not establish a recovery benefit or clinical equivalence to another provider’s offer.

Published offer
BPC-157 single injectable; precise injection route not established in reviewed text
Advertised starting price
BPC-157 $229 first charge; $279 every 28 days afterward
Billing basis
Recurring subscription every 28 days; higher renewal price
Refund boundary
Cancellation stops future renewals; processed charges not automatically reversed, shipped medication may be nonrefundable
State and pharmacy match
Exact product-state eligibility and dispensing pharmacy/license not independently verified

Useful details

  • Explicit first and renewal pricing with 28-day interval
  • Care, medication, cold shipping and check-ins described in package

What to weigh

  • The repeating amount is higher than the introductory price
  • Precise route and product-specific pharmacy/state match remain unresolved

A review of published information, not a treatment experience or a clinical quality rating. Source check: 2026-10-29.

Keep the single product separate from the blends

Promise lists a BPC-157 single product and also uses BPC-157 in Wolverine and KLOW. They are different formulations. This review concerns the single BPC-157 listing, which describes an injectable preparation. We did not establish a more precise injection route from the reviewed detail. Keep the product identity beside any comparison with Pepti or MyNuvara Health.

Budget the renewal rather than the opening offer

The single product displays $229 first and $279 every 28 days thereafter. Those figures should not be collapsed into a $229 monthly headline. Over a three-calendar-month window, a 28-day plan can include four charges, depending on the dates. Use the cost planner to enter the recurring amount and first-payment difference, with the actual start date from the quote.

Read the included-care description

The product page describes clinician review, prescription, medication, cold shipping and check-ins as included. A first-payment authorization is temporary pending approval, under the terms. Ask what happens when the clinician changes or declines the requested plan, and which services may be charged. A package description still needs an identified clinical responsibility and a clear pharmacy handoff.

Before the next refill

The terms provide online, email and phone cancellation routes. Receipt stops future renewals; a processed charge is not automatically reversed. Shipped medication can fall outside the refund boundary. Keep the next charge date and cancellation confirmation where you can find them, rather than treating an ongoing supply arrangement like a one-time purchase.

The details a catalog cannot settle

The platform says treatments vary by location despite its broad coverage language. We have not independently verified the exact BPC product-state pathway, dispensing pharmacy or relevant license. We also have not checked an actual prescription. Current availability needs a product-level answer, including the preparation and route, rather than a general reference to a peptide policy.

Where the offer fits

Promise supplies a clear introductory-versus-renewal distinction and a package description. The practical questions concern the precise product, individual access, follow-up and refund timing. Those are good consultation checklist items. Human evidence should be assessed on its own terms; a visible service price does not establish a recovery benefit or clinical equivalence to another provider’s offer.

Sources & further reading

Primary research, provider documents and policy sources used in this article. Sources do not endorse this publication.

  1. Promise bpc-157 official offering
  2. Promise current catalog
  3. Promise published terms

Source review: 2026-10-29. Provider terms and policy documents can change.

Your choice

A little control over your data.

Analytics cookies are on by default to understand site use and referral placements. You can opt out at any time. Calculator entries are never submitted.

Read the privacy notice